Brief: Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico
24/06/2026 23:28
BRIEF-Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico June 24 (Reuters) - Nurexone Biologic Inc NRX.V:
EXO-TOP, NUREXONE’S WHOLLY OWNED U.S. SUBSIDIARY, ENTERS INTO BINDING MOU FOR NAÏVE EXOSOME DISTRIBUTION IN MEXICO
Source text: ID:nGNXb5JK8V
Further company coverage: NRX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurexone Biologic
See all newsBrief: Nurexone Announces Binding MoU With Made Scientific For U.S. Gmp Manufacturing And Commercial Supply Partnership
Brief: Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors
Brief: Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico
Brief: Nurexone Biologic’S U.S. Subsidiary Exo-Top And Florida-Based Bioxtek Sign Strategic Loi For Exosome Manufacturing And Commercialization
Brief: Nurexone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement